During the COVID-19 pandemic, HMGB1 was identified as a potential therapeutic target for COVID-19-related lung injury and could also serve as a key cytokine for predicting ARDS severity [57]. The gene discussed is HMGB1; the disease is acute respiratory distress syndrome.